Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Open-Label Trial of ADP-A2M4CD8 in Advanced Esophageal or EGJ Cancer
2020-005802-24Phase 2Completed
- Sponsor
- Adaptimmune Therapeutics
- Start
- May 2021
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ADP adoptive cell therapy in esophageal cancer and esophagogastric junction cancer, sponsored by Adaptimmune Therapeutics. Primary endpoint: Objective response rate per RECIST v1.1 by independent review. Started May 2021; status: completed.
02
Drugs
ADP adoptive cell therapy
03
Conditions
esophageal canceresophagogastric junction cancer
Beyond the preview
Go deeper on 2020-005802-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005802-24.